Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.Earlier this month, Immunome announced that it entered into a definitive asset purchase agreement with Ayala to acquire AL102 and related drug candidate AL101. Completion of the transaction remains subject to customary closing conditions.“We are pleased with the progress of the RINGSIDE trial,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome. “The robust enrollment of the Phase 3 portion affirms our excitement for the potential of AL102. We are also encouraged by the rapid
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Appoints Kinney Horn as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Kinney Horn as Chief Business OfficerBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $24.00 price target on the stock.MarketBeat
- Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Sandra M. Swain to Board of Directors [Yahoo! Finance]Yahoo! Finance
IMNM
Sec Filings
- 4/30/24 - Form 8-K
- 4/29/24 - Form 4
- 4/29/24 - Form 3
- IMNM's page on the SEC website